Who are the top shareholders of the Star Health Insu?

The top shareholder of Star Health Insurance is Safecrop Investments India LLP, holding 40.23%. Other significant shareholders include 18 mutual fund schemes with 9.45%, 177 foreign institutional investors with 18.68%, and individual investors with 5.57%.

The top shareholders of Star Health Insurance include a mix of promoters, institutional investors, and individual shareholders. The largest shareholder is Safecrop Investments India LLP, which holds 40.23% of the company. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively own 9.45%, while 177 foreign institutional investors (FIIs) hold 18.68%. The highest public shareholder is ICICI Prudential Pharma Healthcare and Diagnostics Fund, which has a stake of 4.8%. Additionally, individual investors collectively hold 5.57% of the company. <BR><BR>This diverse ownership structure reflects a strong interest from both domestic and international investors.

how big is Star Health Insu?

As of Jun 06, Star Health & Allied Insurance Company Ltd has a market capitalization of 27,559.00 Cr, with net sales of 14,822.20 Cr and net profit of 645.87 Cr over the latest four quarters. Shareholder's funds are 6,670.59 Cr, and total assets amount to 17,409.55 Cr as of the latest annual period ending in Mar 24.

Market Cap: As of Jun 06, the company name is Star Health & Allied Insurance Company Ltd, with a market capitalization of 27,559.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 14,822.20 Cr and the sum of Net Profit is 645.87 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar 24. The Shareholder's Funds are reported at 6,670.59 Cr, and the Total Assets amount to 17,409.55 Cr.

What does Star Health Insu do?

Star Health & Allied Insurance Company Ltd specializes in health insurance and was established in 2005. As of March 2025, it reported net sales of ₹3,798 Cr and a net profit of ₹1 Cr, with a market cap of ₹27,574 Cr.

Overview:<BR>Star Health & Allied Insurance Company Ltd operates in the insurance industry as a large-cap company, specializing in health insurance.<BR><BR>History:<BR>The company was incorporated on 17 June 2005 in Chennai and received regulatory approval from the Insurance Regulatory and Development Authority of India (IRDAI) to commence health insurance operations on 16 March 2006. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,798 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 27,574 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 42.00<BR>- Industry P/E: 23<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.07<BR>- Return on Equity: 9.59%<BR>- Price to Book: 4.08<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Star Health Insu?

As of March 2023, the management team of Star Health Insurance includes Anand Shankar Roy as Managing Director & CEO, along with several nominees and independent directors, such as Rohit Bhasin and Anisha Motwani.

As of March 2023, the management team of Star Health Insurance includes the following individuals:<BR><BR>1. Sumir Chadha - Nominee<BR>2. Deepak Ramineedi - Nominee<BR>3. Utpal Seth - Nominee<BR>4. Rohit Bhasin - Independent Director<BR>5. Anisha Motwani - Independent Director<BR>6. Berjis M Desai - Independent Director<BR>7. Rajeev Kumar Agarwal - Independent Director<BR>8. Anand Shankar Roy - Managing Director & CEO<BR>9. Rajni Sekhri Sibal - Independent Director<BR>10. Jayashree Sethuraman - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of nominees and independent directors, with Anand Shankar Roy serving as the Managing Director and CEO.

When is the next results date for Star Health Insu?

No Upcoming Board Meetings

Has Star Health Insu declared dividend?

No Dividend History Available

Who are the peers of the Star Health Insu?

Star Health Insu's peers include Life Insurance, SBI Life, HDFC Life, ICICI Pru Life, ICICI Lombard, Max Financial, Go Digit General, Niva Bupa Health, and Medi Assist. Star Health Insu has an average management risk and a 1-year return of -7.54%, higher than Life Insurance's -10.43% but lower than its other peers.

Peers: The peers of Star Health Insu are Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Go Digit General, Niva Bupa Health, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard, while Average management risk is found at Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Go Digit General, Star Health Insu, Niva Bupa Health, and Medi Assist Ser. Growth is Excellent at Go Digit General and Niva Bupa Health, while Average growth is noted for Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Star Health Insu, and Medi Assist Ser. Capital Structure is Excellent across all peers.<BR><BR>Return Snapshot: Max Financial has the highest 1-year return at 62.40%, while Life Insurance has the lowest at -10.43%. Star Health Insu's 1-year return is -7.54%, which is higher than Life Insurance but lower than all other peers. Additionally, Medi Assist Ser. has a negative six-month return.

Are Star Health Insu latest results good or bad?

Star Health's latest results are concerning, with a 50.66% decline in net profit and a significant drop in operating profit margin, despite a 10.18% revenue growth. This suggests serious challenges in profitability and operational efficiency, indicating a cautious outlook for investors.

Star Health's latest results indicate a challenging situation for the company. While revenue grew by 10.18% year-on-year to ₹4,080.83 crores, the net profit saw a dramatic decline of 50.66%, falling to ₹54.90 crores. This represents a staggering 79.09% drop compared to the previous quarter. <BR><BR>The operating profit margin also collapsed significantly, dropping from 8.92% in the previous quarter to just 1.83%. This sharp decline raises serious concerns about the company's operational efficiency and cost management. Despite the revenue growth, the substantial decrease in profitability suggests that Star Health is facing significant challenges in maintaining its margins and managing claims effectively.<BR><BR>Overall, the results can be characterized as bad, primarily due to the severe decline in profitability and the concerning trends in operational metrics. Investors may need to approach the stock with caution, given the current financial pressures and the high valuation multiples that seem increasingly unjustified in light of these results.

Is Star Health Insu overvalued or undervalued?

As of October 29, 2025, Star Health Insurance is considered very expensive and overvalued with a PE ratio of 53.01, significantly higher than its peers, and has underperformed the market with a 1-year return of -10.85%.

As of 29 October 2025, the valuation grade for Star Health Insurance has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook. The company is currently assessed as overvalued, with a PE ratio of 53.01, a Price to Book Value of 4.00, and an EV to EBIT of 13.77. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bajaj Finance has a PE ratio of 37.96 and an EV to EBITDA of 20.16, while Life Insurance boasts a much lower PE ratio of 11.8 and an EV to EBITDA of 9.21, highlighting the expensive nature of Star Health Insurance relative to its competitors. Additionally, the company's recent stock performance has been underwhelming, with a 1-year return of -10.85% compared to the Sensex's 5.76%, further reinforcing the perception of overvaluation.

How has been the historical performance of Star Health Insu?

Star Health Insu has shown significant growth, with net sales increasing from 4,626.63 Cr in Mar'21 to 14,822.20 Cr in Mar'25, and profit after tax improving from a loss of 1,085.71 Cr to a profit of 645.86 Cr in the same period. Despite fluctuations in operating profit, total assets rose to 20,433.42 Cr in Mar'25, and cash flow from operations turned positive with a net inflow of 223.00 Cr.

Answer:<BR>The historical performance of Star Health Insu shows a significant growth trajectory in net sales and total operating income over the years, with net sales increasing from 4,626.63 Cr in Mar'21 to 14,822.20 Cr in Mar'25. Other operating income also rose from 423.69 Cr in Mar'21 to 1,279.03 Cr in Mar'25, contributing to a total operating income of 16,101.23 Cr in Mar'25, up from 5,050.32 Cr in Mar'21. Despite this growth, the operating profit (PBDIT) has fluctuated, peaking at 1,128.85 Cr in Mar'24 before declining to 861.05 Cr in Mar'25. Profit after tax has shown improvement, moving from a loss of 1,085.71 Cr in Mar'21 to a profit of 645.86 Cr in Mar'25. The company's total assets have also increased significantly, reaching 20,433.42 Cr in Mar'25 from 5,980.00 Cr in Mar'20, while total liabilities rose to 20,433.42 Cr in Mar'25 from 5,980.00 Cr in Mar'20. Cash flow from operating activities has been positive, with a net cash inflow of 223.00 Cr in Mar'25, compared to a net outflow of 1,221.00 Cr in Mar'22.<BR><BR>Breakdown:<BR>Star Health Insu has demonstrated robust growth in its financial metrics over the years. Net sales surged from 4,626.63 Cr in Mar'21 to 14,822.20 Cr in Mar'25, reflecting a strong demand for its services. Other operating income also increased significantly, contributing to a total operating income that rose from 5,050.32 Cr in Mar'21 to 16,101.23 Cr in Mar'25. However, the operating profit (PBDIT) experienced fluctuations, with a peak in Mar'24 at 1,128.85 Cr, followed by a decline to 861.05 Cr in Mar'25. The profit after tax improved notably, transitioning from losses in previous years to a profit of 645.86 Cr in Mar'25. The total assets of the company expanded impressively, reaching 20,433.42 Cr in Mar'25, while total liabilities mirrored this growth. Cash flow from operating activities remained positive, indicating a healthy operational performance, with a net cash inflow of 223.00 Cr in Mar'25, contrasting with the challenges faced in earlier years.

Is Star Health Insu technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to positive short-term signals, but mixed longer-term indicators suggest caution.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD being bullish and the daily moving averages indicating a mildly bullish trend. However, the monthly MACD is mildly bearish, and the KST shows a bearish signal on the monthly timeframe. The Bollinger Bands are mildly bullish on the weekly but sideways on the monthly, indicating some indecision. Overall, while there are positive signals in the short term, the mixed signals in the longer timeframes suggest caution.

Should I buy, sell or hold Star Health Insu?

Which are the latest news on Star Health Insu?

Why is Star Health Insu falling/rising?

As of 04-Dec, the stock price of Star Health & Allied Insurance Company Ltd is declining, currently at 465.00, reflecting a 1.51% decrease. The stock has faced consistent declines due to poor financial results, high valuation concerns, and significant drops in net sales, leading to negative investor sentiment.

As of 04-Dec, the stock price of Star Health & Allied Insurance Company Ltd is falling, currently at 465.00, which reflects a decrease of 7.15 (-1.51%). The stock has been on a downward trend, having lost 5.24% over the past week and has experienced consecutive declines for the last five days. This consistent underperformance is highlighted by the stock's negative returns of -5.10% over the past year, significantly lagging behind the benchmark Sensex, which has gained 5.32% in the same period.<BR><BR>Several factors contribute to this decline. The company reported poor financial results for the quarter ending September 25, with a profit before tax (PBT) falling by 61.6% compared to the previous four-quarter average, and a profit after tax (PAT) dropping by 62.7%. Additionally, the stock's valuation appears expensive, with a price-to-book value of 3.7, which is higher than the average historical valuations of its peers. This premium valuation, coupled with a return on equity (ROE) of only 7.2, raises concerns among investors.<BR><BR>While there are some positive indicators, such as strong long-term fundamental strength with a 19.34% compound annual growth rate (CAGR) in operating profits and high institutional holdings at 34.59%, these factors have not been sufficient to offset the negative sentiment surrounding the stock. The significant decline in net sales, which has grown at an annual rate of -50.25%, further exacerbates the situation, leading to a lack of confidence among investors and contributing to the stock's falling price.